![Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk | Nature Communications Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-34408-0/MediaObjects/41467_2022_34408_Fig1_HTML.png)
Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk | Nature Communications
![Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma - ScienceDirect Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S000649712100690X-grabsf1.jpg)
Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma - ScienceDirect
![Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet](https://www.thelancet.com/cms/attachment/f8ef32d8-e2f9-4baf-b793-4a1ee10fea30/gr2_lrg.jpg)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet
![Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet](https://www.thelancet.com/cms/attachment/3cc43973-9161-436d-bf55-be5a18c2f548/gr1.gif)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet
![NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)](https://jnccn.org/cover/journals/jnccn/17/6/cover.jpg)